News

April 7, 2019

HistoSonics' tech attracts health care heavyweights

Ann Arbor-based HistoSonics Inc. plans to announce Monday that it has closed on a venture-capital funding round of $54 million […]
January 7, 2019

‘Flyover Tech’ Is All the Rage at the 2019 J.P. Morgan Healthcare Investment Conference

On Monday, the 37th Annual JP Morgan Healthcare Investment Conference kicks off in San Francisco—a week-long orgy of PowerPoint decks, […]
1 4 5 6

Last updated on September 3, 2024

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on September 5, 2024
X New Twitter Logo
© 2019-2024 HistoSonics®. All rights reserved.